Login to Your Account



Earnings Roundup


Thursday, February 16, 2012
• Incyte Corp., of Wilmington, Del., reported the first revenue from JAK inhibitor Jakafi (ruxolitinib), approved in November 2011 for intermediate or high-risk myelofibrosis, with fourth-quarter net product revenue of $2 million, besting consensus estimates by about $1 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription